retatrutide phase 2 trial results Shows Promising in Type Diabetes and Obesity | Michael Weintraub, MD posted on the topic Retatrutide Phase 2: Type 2
Description
Retrieved on July 29, 2025 from Novo Nordisk (a)

Again, discard the vial

Taken together, with the overlap between OA risk factors and the metabolic syndrome, the demonstrated anti-inflammatory activities of GLP-1 in several tissues [10] and the expression of GLP-1R in joint tissues, GLP-1 analogues may be good therapeutic candidates for treating OA
The GLP-1 revolution shows no signs of slowing down

Progress in therapies for myocardial ischemia reperfusion injury
